Cancer drug capmatinib gets extended safety check in ongoing study
NCT ID NCT03040973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study offers continued treatment with capmatinib for people with advanced solid tumors that depend on a protein called cMET. It includes 29 participants who were already benefiting from capmatinib in a previous Novartis trial. The main goal is to monitor long-term safety and side effects over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WHICH ARE CMET-DEPENDENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200433, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Perugia, PG, 06129, Italy
-
Novartis Investigative Site
Milan, 20141, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Madrid, 28040, Spain